Risk factors and prognosis for the development of acute kidney injury in patients using colistin in the intensive care unit: A retrospective cohort study

Basit Öğe Kaydı
dc.authoridAlisik, Murat/0000-0003-0434-3206
dc.authoridDeniz, Mustafa/0000-0002-1243-3028
dc.contributor.authorDeniz, Mustafa
dc.contributor.authorAlisik, Murat
dc.date.accessioned2024-09-25T19:56:09Z
dc.date.available2024-09-25T19:56:09Z
dc.date.issued2024
dc.departmentAbant İzzet Baysal Üniversitesien_US
dc.description.abstractColistin, an antibiotic of polymyxin group, has recently been increasingly used in the treatment of multidrug resistant gram-negative bacteria. However, it has serious adverse effects such as acute kidney injury (AKI). We aimed to determine the factors affecting the development of AKI due to colistin, which has serious adverse effects, such as nephrotoxicity and neurotoxicity. We retrospectively analyzed the data of patients who received colistin for multidrug resistant gram-negative sepsis in adult intensive care units between January 2020 and December 2022. Demographic data, blood test results, concomitant drug use, need for renal replacement therapy, and mortality were recorded. Kidney damage was assessed according to the Kidney Disease Improving Global Outcomes criterion. We obtained data from 103 patients, 45 (43.7%) of whom were women. The most common comorbidity was a neurological disorder. Renal damage developed in 59.2% of patients. Renal replacement was required in 50.8% of the patients. Among patients who received colistin, 64.1% died. The use of vasopressors, diuretics, nephrotoxic agents with colistin, advanced age, and hypoalbuminemia were more common in patients with renal injury. Multivariate regression analysis showed that vasopressor use, prior creatinine elevation, and diuretic use were independent risk factors for colistin-induced AKI. Vasoactive agent use, previous kidney injury, and furosemide use were independent risk factors for colistin-induced nephrotoxicity. Considering these factors may be instructive for better monitoring of patients when colistin is required in intensive care units.en_US
dc.identifier.doi10.1097/MD.0000000000036913
dc.identifier.issn0025-7974
dc.identifier.issn1536-5964
dc.identifier.issue2en_US
dc.identifier.pmid38215139en_US
dc.identifier.scopus2-s2.0-85182303246en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1097/MD.0000000000036913
dc.identifier.urihttps://hdl.handle.net/20.500.12491/13146
dc.identifier.volume103en_US
dc.identifier.wosWOS:001142435500002en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofMedicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzYK_20240925en_US
dc.subjectacute kidney injuryen_US
dc.subjectcolistinen_US
dc.subjectintensive care uniten_US
dc.subjectmultidrug resistanceen_US
dc.subjectvasopressorsen_US
dc.titleRisk factors and prognosis for the development of acute kidney injury in patients using colistin in the intensive care unit: A retrospective cohort studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu